A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.
Inclusion Criteria: - Type 2 diabetes - Age min. 50 years at screening and concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or chronic heart failure OR age min. 60 years at screening and other specified risk factors of cardiovascular disease - HbA1c: 7.0% or above - Anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s) Exclusion Criteria: - Type 1 diabetes - Use of a glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP-4) inhibitor within the 3 months prior to screening (trial start) - Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Short-term use of other insulin during this period in connection with intercurrent illness is allowed, at Investigator's discretion
Aracajú, 49020-270, Brazil
Århus C, 8000, Denmark
Angermünde/OT Wolletz, 16278, Germany
Karlsbad, 76307, Germany
Saint Ingbert-Oberwürzbach, 66386, Germany
Crete, 71001, Greece
Hyderabad, Andhra Pradesh 500034, India
Hyderbad, Andhra Pradesh 500 012, India
Chandigarh, Punjab 160012, India
Thriruvananthapuram, 695 032, India
Mora de Ebre, 43740, Spain
Mostoles - Madrid -, 28935, Spain
Kaoshiung, 807, Taiwan
Devon, EX2 5DW, United Kingdom
Livington, EH54 6PP, United Kingdom
West Midlands, B71 4HJ, United Kingdom